Danny Rischin, MD, MBBS, FRACP, shares his insights on cemiplimab as a treatment for patients with metastatic cutaneous squamous cell carcinoma.
Danny Rischin, MD, MBBS, FRACP, director, division of cancer medicine, and head, department of medical oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, shares his insights on cemiplimab (Libtayo) as a treatment for patients with metastatic cutaneous squamous cell carcinoma (mCSCC).
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More